Perspectives on Treatment of Metastatic Castration-Resistant Prostate Cancer

被引：29
|
作者：
Merseburger, Axel S. [1 ]
Bellmunt, Joaquim [2 ]
Jenkins, Cheryl [3 ]
Parker, Chris [4 ]
Fitzpatrick, John M. [5 ,6 ]
机构：
[1] Hannover Med Sch, Dept Urol & Urol Oncol, D-30625 Hannover, Germany
[2] Univ Hosp Mar, Inst Invest Med, Med Oncol Serv, Barcelona, Spain
[3] Rocket Sci Med Commun, Wantage, Oxon, England
[4] Royal Marsden Natl Hlth Serv Fdn Trust, Sutton, Surrey, England
[5] Mater Misericordiae Hosp Univ Coll, Dept Surg, Dublin, Ireland
[6] Irish Canc Soc, Dublin, Ireland
来源：
ONCOLOGIST | 2013年 / 18卷 / 05期
关键词：
Metastatic castration-resistant; Prostate cancer; Treatment; Docetaxel; Cabazitaxel; Abiraterone acetate; Enzalutamide; CIRCULATING TUMOR-CELLS; ANDROGEN RECEPTOR GENE; MITOXANTRONE PLUS PREDNISONE; PHASE-II TRIAL; CLINICAL-TRIALS; BONE METASTASES; SIPULEUCEL-T; SKELETAL COMPLICATIONS; ABIRATERONE ACETATE; INCREASED SURVIVAL;
D O I：
10.1634/theoncologist.2012-0478
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
The arrival of several new agents-cabazitaxel, abiraterone acetate, enzalutamide, and radium-223-is changing the treatment options and management of patients with metastatic castration-resistant prostate cancer (mCRPC). Many other novel agents are also being investigated. As new drugs become approved, new treatment strategies and markers to best select which patients will best respond to which drug are needed. This review article is a summary of a European Treatment Practices Meeting, which was convened to discuss these latest data on novel agents and current treatment strategies in the mCRPC setting.
引用
收藏
页码：558 / 567
页数：10
相关论文
共 50 条
  • [31] Radium-223 In The Treatment Of Metastatic Castration-Resistant Prostate Cancer
    Vazzana, C.
    Morano, S.
    Di Lascio, A.
    Grana, C.
    Chinol, M.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2017, 44 : S880 - S880
  • [32] Treatment and trials in non-metastatic castration-resistant prostate cancer
    Lokeshwar, Soum D.
    Klaassen, Zachary
    Saad, Fred
    NATURE REVIEWS UROLOGY, 2021, 18 (07) : 433 - 442
  • [33] Clinical use of abiraterone in the treatment of metastatic castration-resistant prostate cancer
    Zobniw, Chrystia M.
    Causebrook, Alanna
    Fong, Mei Ka
    RESEARCH AND REPORTS IN UROLOGY, 2014, 6 : 97 - 105
  • [34] Treatment and trials in non-metastatic castration-resistant prostate cancer
    Soum D. Lokeshwar
    Zachary Klaassen
    Fred Saad
    Nature Reviews Urology, 2021, 18 : 433 - 442
  • [35] Metastatic Castration-Resistant Prostate Cancer: Advances in Treatment and Symptom Management
    Kulasegaran, Tivya
    Oliveira, Niara
    CURRENT TREATMENT OPTIONS IN ONCOLOGY, 2024, 25 (07) : 914 - 931
  • [36] Castration-resistant metastatic prostate cancer: current status and treatment possibilities
    Joan Carles
    Daniel Castellano
    Miguel Ángel Climent
    Pablo Maroto
    Rafael Medina
    Antonio Alcaraz
    Clinical and Translational Oncology, 2012, 14 : 169 - 176
  • [37] New treatment options for patients with metastatic castration-resistant prostate cancer
    Higano, Celestia S.
    CANCER TREATMENT REVIEWS, 2012, 38 (05) : 340 - 345
  • [38] Evolution of the Treatment Paradigm for Patients with Metastatic Castration-Resistant Prostate Cancer
    Malik, Zafar
    Payne, Heather
    Ansari, Jawaher
    Chowdhury, Simon
    Butt, Mohammad
    Birtle, Alison
    Sundar, Santhanam
    Eswar, Chinnamani Vee
    Hughes, Simon
    Bahl, Amit
    ADVANCES IN THERAPY, 2013, 30 (12) : 1041 - 1066
  • [39] Treatment Sequencing in Metastatic Castration-Resistant Prostate Cancer: A Clinical Commentary
    Stein, Cy A.
    CLINICAL GENITOURINARY CANCER, 2015, 13 (05) : 407 - 409
  • [40] Current and emerging treatment modalities for metastatic castration-resistant prostate cancer
    Bracarda, Sergio
    Logothetis, Christopher
    Sternberg, Cora N.
    Oudard, Stephane
    BJU INTERNATIONAL, 2011, 107 : 13 - 20
12345